Chimeric antigen receptor T cell immunotherapies - MediSix Therapeutics

Drug Profile

Chimeric antigen receptor T cell immunotherapies - MediSix Therapeutics

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediSix Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research T cell lymphoma; T-cell leukaemia

Most Recent Events

  • 11 Sep 2017 MediSix Therapeutics enters into a licensing agreement for certain patent and technology rights from the National University of Singapore
  • 11 Sep 2017 Early research in T-cell leukaemia in Singapore (unspecified route)
  • 11 Sep 2017 Early research in T-cell lymphoma in Singapore (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top